Engflag

Evzio

Quick links to important sections

Evzio

Selected form

Evzio_EN

Method of action: All Other Therapeutic Products, Antidote, Blocking Opiate Receptors

Treatment option: Depression, Poisoning, Opioid Overdose

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Evzio

What is Evzio? A Foundational Overview

Evzio is a specialized medical product designed for use in a life-threatening emergency, providing rapid intervention for acute opioid effects. This product is defined by its core active ingredient, Naloxone Hydrochloride, and its unique delivery mechanism, positioning it as a critical tool for immediate, temporary support outside of professional medical settings.

Quick Facts
Active ingredient Naloxone Hydrochloride
Form Solution for Injection in Auto-injector
Pharmacological class Pure Opioid Antagonist
General purpose Acute reversal of opioid effects
Origin Synthetic

Evzio: Definition and Pharmacological Classification

Evzio is a Drug-Device Combination Product used as an agent for acute reversal of central nervous system depression caused by opioids. The active component, Naloxone Hydrochloride, is classified as a pure opioid antagonist. This synthetic substance works by quickly binding to the mu -opioid receptors in the brain with high affinity, competitively blocking or displacing opioid molecules already attached to those sites. The primary general purpose of this immediate action is to counter the most dangerous opioid effect—the critical slowing or stopping of breathing—establishing Evzio's utility as a crucial emergency measure in opioid-related crises. The clinical recognition of Naloxone's life-saving importance is evidenced by its inclusion on the World Health Organization (WHO) Model List of Essential Medicines.

Composition and Unique Delivery System

The medicine is composed of Naloxone Hydrochloride dissolved in a sterile aqueous solution for injection. Naloxone is a synthetic compound derived from the opioid alkaloid thebaine. The key differentiating feature of Evzio is its specific presentation as an auto-injector device. This system is distinguished from standard pre-filled syringes or nasal spray forms by being engineered to automatically deliver the solution via the Intramuscular (IM) or Subcutaneous (SC) route upon activation. This design prioritizes rapid, simplified administration, which is crucial for individuals who are not medical professionals intervening in an acute, time-sensitive scenario.

Regulatory References

  1. Naloxone on the WHO Electronic Essential Medicines List (eEML)

What side effects are possible with Evzio?

Possible Side Effects and Safety Information

Key Safety Restrictions and Warnings

Evzio is contraindicated in patients with a known hypersensitivity to naloxone hydrochloride or any of its ingredients. The primary safety concerns relate to the immediate and rapid reversal of opioid effects:

  • Recurrent Respiratory/CNS Depression: The effect of most opioids is likely to outlast the effect of naloxone. This creates a risk that breathing problems and central nervous system depression will return after initial improvement. Continued patient surveillance until emergency medical services arrive is essential, and repeat doses may be required.
  • Precipitation of Severe Opioid Withdrawal: Administration to an opioid-dependent individual may precipitate an acute and severe abstinence syndrome. Signs can include body aches, fever, sweating, piloerection (goosebumps), shivering, nervousness, restlessness, irritability, nausea, vomiting, and diarrhea. In neonates, this withdrawal may include convulsions, excessive crying, and hyperactive reflexes, which can be life-threatening if not immediately addressed.
  • Cardiovascular Effects: Adverse cardiovascular events, including cardiac arrest, hypertension, hypotension, and arrhythmias, have been reported following abrupt reversal of opioid depression, primarily in postoperative patients with pre-existing heart conditions.
Adverse Reaction Category Examples of Reported Signs
Opioid Withdrawal Body aches, fever, sweating, rhinorrhea, piloerection, nausea, vomiting, diarrhea, abdominal cramps, restlessness.
Cardiovascular Tachycardia, hypertension, hypotension, cardiac arrest (rarely).
Injection Site (Local) Localized erythema (redness) and pressure markings (most common event in studies).

High-Level Safety Note

Evzio is intended solely for emergency use and is not a substitute for professional medical care. The requirement for repeat doses is dependent upon the amount and type of opioid being antagonized. Its use in the case of a suspected overdose is generally considered to have no effect if opioids are not present.

Overdose and Emergency Response

Overdose and When to Seek Help

Evzio (naloxone) is an emergency treatment intended to reverse the effects of opioid overdose. It is not a substitute for professional medical care.

Documented Risks and Manifestations

Official regulatory information emphasizes two primary risks following administration. First, the rapid reversal of opioid effects may precipitate acute opioid withdrawal syndrome in opioid-dependent individuals. Symptoms can include body aches, diarrhea, nausea, vomiting, shivering, and increased heart rate. Second, serious adverse events have been reported in connection with abrupt reversal, including ventricular fibrillation, pulmonary edema, and cardiac arrest.

Urgent Medical Attention Required

Always seek emergency medical care immediately after administering Evzio. This instruction is critical regardless of the patient's initial response to the dose.

Regulatory documents highlight that the duration of action for many opioids exceeds that of naloxone. This creates a documented risk of re-narcotization (the return of respiratory or CNS depression). Continuous patient surveillance until emergency personnel arrive is mandatory, and repeated doses of Evzio, if available, should be administered every 2 to 3 minutes if the patient relapses or does not respond adequately.

Therapeutic Uses of Evzio

What Evzio Treats: Main Uses and Benefits

Evzio is a specialized medical product generally considered relevant for the management of a life-threatening emergency, and is commonly used for the immediate, supportive management of acute opioid effects. Its therapeutic benefit provides supportive relief relevant to the temporary support of key functions during an acute event. Such information is relevant for therapeutic understanding, establishing its use in emergency settings.

Its therapeutic utility is relevant for addressing key symptoms, including symptom clusters related to severe respiratory depression and profound CNS depression. Evzio is typically utilized during acute symptomatic episodes—specifically known or presumed opioid overdose—in scenarios outside of a controlled medical environment. This medication may assist with temporary support relevant to the restoration of spontaneous respiration and supports the easing of unresponsiveness and the restoration of alertness.

This application is relevant for easing symptoms associated with acute changes across patient groups, including adults and pediatric patients, and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Therapeutic Focus
Symptom Domain Critical Respiratory Impairment
Clinical Context Used when symptoms become temporarily overwhelming
Patient Benefit Supports the patient during difficult episodes by easing distress

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Evzio? — Official Regulatory Information

Evzio (naloxone hydrochloride injection) is indicated by regulatory authorities for use in adult and pediatric patients as emergency treatment for known or suspected opioid overdose. Eligibility for the medicine is defined primarily by absolute exclusions and specific patient conditions requiring conditional use, as documented in the FDA Prescribing Information.

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients known to be hypersensitive to naloxone hydrochloride or to any other ingredients in the formulation.
Age-related eligibility rules The medicine is indicated for all pediatric patients; however, special administration technique is noted for patients under the age of one year.
Condition-specific eligibility rules Opioid Dependent Individuals: Use may precipitate an acute abstinence syndrome and requires caution.
Cardiovascular Disorders: Patients with pre-existing cardiovascular disorders require caution and close monitoring due to the potential for adverse cardiovascular effects.
Pregnancy and lactation eligibility status Use in pregnant women may cause withdrawal symptoms in the unborn baby. It is unknown whether naloxone is excreted in human breast milk.

The eligibility profile strictly prohibits use only in cases of known hypersensitivity to the drug's components. All other population groups, including those who are opioid dependent or have certain pre-existing conditions, are eligible for use, but with formal regulatory warnings regarding conditional use and the need for medical surveillance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Evzio (Naloxone Hydrochloride) is defined by its role as a pure opioid antagonist, and its official interaction profile is structured around pharmacodynamic principles, as documented in regulatory labeling.

Documented Pharmacodynamic Interactions

Interacting Product Category Official Interaction Description
Opioids (General) Competitive antagonism results in the rapid reversal of central nervous system and respiratory depression.
Partial Opioid Agonists (e.g., Buprenorphine) Reversal of respiratory depression may be incomplete, requiring repeat administration for sufficient antagonism.
Drugs with similar adverse CV effects Abrupt reversal of the opioid effect may cause adverse cardiovascular events, particularly when combined with these other drug types.

Regulatory Constraints and Considerations

The short duration of action of Naloxone relative to most opioids creates a mandatory timing constraint. This pharmacodynamic mismatch requires patients to be kept under continued surveillance and necessitates the administration of additional doses as needed.

Furthermore, use in opioid-dependent individuals is officially documented to precipitate severe opioid withdrawal, which is a defined consequence of the interaction. The label does not list formal pharmacokinetic interactions (CYP enzymes or transporters) or contraindicated drug-drug combinations.

Mechanism of Action

Evzio (naloxone) is a medication that functions as a competitive antagonist at the mu-opioid receptor (MOR). Its core mechanism is to competitively bind to the MOR, which prevents opioid agonist-mediated signal transduction. Evzio exhibits high binding affinity for the mu-opioid receptor, enabling it to rapidly displace full opioid agonists from the receptor site. This displacement action restores the physiological activity of mathrmGmathrmi/mathrmo signaling pathways that modulate key central nervous system (CNS) centers, including those that control respiration. The underlying mechanism prevents the activation of inhibitory mathrmGmathrmi/mathrmo signaling pathways caused by agonist binding. This molecular event terminates the downstream inhibition of adenylyl cyclase, thereby preventing the mathrmK^+ channel opening responsible for the observed physiological effects.

Dosage and Administration Information

How Evzio is Used

Evzio is a specialized product designated for administration as acute, short-term emergency therapy in non-healthcare settings, serving as an immediate measure until professional medical assistance is available. The drug is delivered through a single-use auto-injector device and is approved for administration via intramuscular (IM) or subcutaneous (SC) injection. The official site for injection is the anterolateral aspect of the thigh, and the device is engineered to allow administration through clothing if necessary to prioritize the speed of response.

Dosing and Administration Schedule

The standard initial dose is the full quantity delivered by the auto-injector, regardless of whether the specific device strength is 0.4 mg or 2 mg. The administration schedule is intermittent and as-needed; if the patient does not achieve the desired response or relapses, an additional dose may be given every 2 to 3 minutes. This repeat dosing is maintained until medical professionals arrive to take over patient care.

Population and Procedural Context

The official labeled dose is the same for both adults and pediatric patients. For infants under one year old, the high-level procedural requirement is that the caregiver must pinch the thigh muscle before administration. The official use protocol requires that the solution be visually inspected to ensure it is clear and colorless prior to use, and includes the mandatory requirement to immediately seek emergency medical assistance following the first dose.

Recent Clinical Evidence

Evzio: Recent Clinical Evidence

Evzio (naloxone auto-injector) is approved for the emergency treatment of known or suspected opioid overdose. Research focused on the compound's ability to rapidly reverse the central nervous system and respiratory depression caused by natural or synthetic opioids.

Clinical Trial Findings

Studies evaluating naloxone auto-injectors have primarily focused on demonstrating the pharmacological effect and rapid delivery of the dose, which is critical in an emergency setting. The key research objectives included:

Research Objective Primary Finding/Evaluation
Pharmacokinetics Assessment of time to peak plasma concentration, demonstrating rapid absorption after administration.
Bioavailability Comparison of the auto-injector delivery system to standard intramuscular injection of naloxone.
Safety and Tolerability Evaluation of adverse events following administration, noting that immediate withdrawal symptoms are common due to naloxone's function as an opioid antagonist.

Efficacy and Mechanism

Research has explored how the rapid delivery of naloxone acts as a competitive antagonist at opioid receptors. By binding to these receptors, naloxone reverses the effects of opioid agonism. Clinical trials examined this reversal by tracking vital signs, specifically the improvement of respiratory rate in patients presenting with opioid-induced respiratory depression. Studies have demonstrated consistent, rapid reversal of respiratory depression when administered promptly.

Public Health Research

In addition to clinical efficacy, research has addressed the utility of Evzio in community settings. Studies have evaluated the ease of use by non-healthcare professionals and the impact of widespread availability on reducing overdose fatalities. Findings generally support the compound’s role as an accessible, life-saving intervention.

How should Evzio be stored and disposed of?

Evzio (naloxone auto-injector) must be stored and handled according to specific regulatory requirements to maintain product integrity.

Storage Conditions Details
Temperature Store at controlled room temperature: 59 F to 77 F (15 C to 25 C). Do not refrigerate or freeze.
Protection Keep the device in its original outer case to protect the solution from light.
Integrity Check the viewing window; the solution must be clear and colorless. Replace the auto-injector if it is discolored, cloudy, or if the expiration date is reached.
Safety Keep the Evzio auto-injector out of the sight and reach of children.

Used auto-injectors must not be thrown into household trash. After use, the device should be placed back into its outer case and taken to a healthcare facility for proper disposal in a sharps container. Unused or expired auto-injectors should be discarded via a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Evzio found in:

A-Z Index: